Violeta Stoyanova-Beninska
Overview
Explore the profile of Violeta Stoyanova-Beninska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hewitt E, Bouche G, Alencar A, Bigelsen S, Radu R, Stoyanova-Beninska V, et al.
Cancer Manag Res
. 2025 Mar;
17:429-440.
PMID: 40046652
Pancreatic cancer (PC) remains one of the most challenging malignancies to treat. Current therapeutic options are unsatisfactory, and there is an urgent need for more effective and less toxic drugs...
2.
Palomo G, Pose-Boirazian T, Naumann-Winter F, Costa E, Duarte D, Kalland M, et al.
Mol Ther
. 2024 Nov;
PMID: 39489919
To provide insight into regulatory decision-making at the time of granting initial orphan designation by the Committee for Orphan Medicinal Products, we have conducted a retrospective analysis for viral vector-mediated...
3.
Jadoenathmisier K, Stoyanova-Beninska V, Soons I, Leufkens H, Bloem L, Pasmooij A
Eur J Pharm Sci
. 2024 Aug;
202:106871.
PMID: 39111579
Background: In the European Union, rare diseases are defined as diseases that affect maximum 5 in 10,000 citizens. These diseases are typically associated with a high unmet medical need. To...
4.
Prilla S, Groeneveld S, Pacurariu A, Restrepo-Mendez M, Verpillat P, Torre C, et al.
Clin Pharmacol Ther
. 2024 Jul;
116(5):1188-1197.
PMID: 38962830
Studies using real-world data (RWD) can complement evidence from clinical trials and fill evidence gaps during different stages of a medicine's lifecycle. This review presents the experience resulting from the...
5.
Moseley J, Leest T, Larsson K, Magrelli A, Stoyanova-Beninska V
Eur J Ophthalmol
. 2024 Mar;
34(6):1631-1641.
PMID: 38500388
Inherited Retinal Dystrophies (IRD) are diverse rare diseases that affect the retina and lead to visual impairment or blindness. Research in this field is ongoing, with over 60 EU orphan...
6.
Kalland M, Pose-Boirazian T, Palomo G, Naumann-Winter F, Costa E, Matusevicius D, et al.
Gene Ther
. 2024 Mar;
31(7-8):366-377.
PMID: 38480914
Adoptive cell therapy (ACT), particularly chimeric antigen receptor (CAR)-T cell therapy, has emerged as a promising approach for targeting and treating rare oncological conditions. The orphan medicinal product designation by...
7.
Palomo G, Pose-Boirazian T, Naumann-Winter F, Costa E, Duarte D, Kalland M, et al.
Mol Ther
. 2023 Oct;
31(12):3414-3423.
PMID: 37794679
In 2000, the European Union (EU) introduced the orphan pharmaceutical legislation to incentivize the development of medicinal products for rare diseases. The Committee for Orphan Medicinal Products (COMP), the European...
8.
Kerpel-Fronius S, Stoyanova-Beninska V, Giannuzzi V, Sun Z
Front Med (Lausanne)
. 2023 Jun;
10:1206753.
PMID: 37261118
No abstract available.
9.
Giannuzzi V, Stoyanova-Beninska V, Hivert V
Front Pharmacol
. 2022 Dec;
13:1089033.
PMID: 36506540
No abstract available.
10.
Mulder J, van Stuijvenberg O, van Hennik P, Voest E, Pasmooij A, Stoyanova-Beninska V, et al.
Front Med (Lausanne)
. 2022 Jul;
9:893400.
PMID: 35775007
There are currently four anti-cancer medicinal products approved for a tissue-agnostic indication. This is an indication based on a common biological characteristic rather than the tissue of origin. To date,...